Wednesday, October 13, 2010
Dr. Michael Snyderman, an ME/CFS patient with chronic lymphocytic leukemia (CLL), began a trial of two HIV drugs shown to have efficacy in treating XMRV in test tube studies. Here's the poster presentation that Snyderman, who's an oncologist, is presenting at MD Anderson Cancer Center in Houston, Texas, at 7 p.m. this evening. Snyderman concludes on the poster:
"A patient with CFS and CLL with adverse prognostic factors was shown to have XMRV in plasma and CLL cells. Within the first 100 days of treatment with AZT and raltegravir, he showed multiple benefits simultaneous with disappearance of infectious XMRV. These findings suggest that XMRV is etiological for both the CLL and CFS and that virus-direct treatment was beneficial in this patient. Further CLL patients should be studied especially as CLL has been statistically associated with an increased risk for other neoplasia. Questions to be answered are what neoplasms are associated with XMRV, will existing antiretrovirals have antineoplasticactivity in these neoplasms and what is the optimal combination of antiretroviral drugs."
Snyderman continues to have more energy on the drug cocktail. However, the doctor's trisomy 12 marker--which is elevated in 25 percent of patients with CLL--initially dipped significantly on the drugs, but has begun to rise again.
Posted Wednesday, October 13, 2010